10F.9G2, a monoclonal antibody with high antibody-dependent cellular cytotoxicity, has an off-target effect that involves the reduction of CD8+ T cells. This surpasses the on-target effect, namely ...

The engineering and functional characterization of the Fc domain are key to therapeutic antibodies’ efficacy, safety, and pharmacokinetics. The Fc domain is responsible for mediating interactions with ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

GUANGZHOU, China, Jan. 14, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced the publication of the Phase I clinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 ...

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Mothers with intrauterine transmission of human cytomegalovirus (CMV) to their newborns despite preconception immunity had higher levels of neutralizing antibodies but had weaker antibody-dependent ...

In therapeutic antibody development the fragment crystallizable (Fc) region is far more than just an antigen-binding aid; it's role is much larger, functioning as the antibody’s functional control ...

Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...